In this issue:
Paediatric MS severity score in a large US cohort
Five-years of ocrelizumab in relapsing MS
Personalised extended interval dosing of natalizumab in MS
A phase 2 trial of laquinimod in PPMS
Incident depression in patients with MS
Nabiximols discontinuation rate in MS
Longitudinal development of peripapillary hyper-reflective ovoid masslike structures in MS
Decreasing impact of late relapses on disability worsening in SPMS
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab
Ocrelizumab induces durable relapsing disease inhibition in MS
Please login below to download this issue (PDF)